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CObjectives: To investigate which factors and criteria are used in pri-
ority setting of pharmaceuticals, in what contexts health economic
evaluations are used, and barriers to the use of health economic
evaluations at micro, meso, and macro health-care levels.
Methods: The search for empirical articles was based on the MeSH
index (Medical Substance Heading), including the search terms “eco-
nomic evaluation,” “cost-effectiveness analysis,” “cost-utility anal-
ysis,” “cost-benefit analysis,” “pharmacoeconomic,” AND “drug
cost(s),” AND “eligibility determination,” AND “decision-making,”
AND “rationing,” AND formulary. The following databases were
searched: PubMed, EconLit, Cochrane, Web of Science, CINAHL, and
PsycINFO. More than 3100 studies were identified, 31 of which were
included in this review. Results: The use of health economic evalu-
ations at all three health-care levels was investigated in three coun-
tries (United States [US], United Kingdom [UK], and Sweden). Postal
and telephone survey methods dominated (n  17) followed by in- O
sines
al So
doi:10.1016/j.jval.2010.10.036erviews (n  13), document analysis (n  10), and observations of
roup deliberations (n  9). The cost-effectiveness criterion was
ost important at the macro level. A number of contextual uses of
ealth economic evaluations were identified, including importantly
he legitimizing of decisions, structuring the priority-setting pro-
ess, and requesting additional budgets to finance expensive
harmaceuticals. Conclusion: Factors that seem to support the in-
reased use of health economic evaluations are well-developed
rameworks for evaluations, the presence of health economic skills,
nd an explicit priority-setting process. Differences in how economic
valuations are used at macro, meso, and micro levels are attributed to dif-
erences in the preconditions at each level.
eywords: economic evaluation, literature review, pharmaceutical, pri-
rity setting.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
A (formal) health economic evaluation can be described as an in-
vestment appraisal related to health care or health, in which both
costs and consequences (e.g., utility) are compared for two or more
alternatives. Despite the growing number of health economic
evaluations, little is known about how these studies are used in
medical decision making. For example, are health economic eval-
uations even used, and if so, by whom and when? A previous
literature review of the use of health economic evaluations in gen-
eral [1] suggested that health economic evaluations are used at all
three (macro, meso, and micro) health-care levels. Macro-level de-
cision makers are those with a national or regional health-care
perspective and who coordinate the use of health-care resources
outside health-care organizations. They are therefore responsible
for the availability of effective and affordable health care intended
for the whole population. Meso-level decision makers are involved
in decisions that are oriented inside health-care organizations, for
example, formulary decisions or the development of local clinical
guidelines. The third level is the micro level, which covers the
activities of individual prescribers at the patient level.
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Published by Elsevier Inc.The proportion of all cost-utility analyses focusing on pharma-
ceuticals increased from 33.6% for the period 1990 to 1995 to 47.3%
for the period 2001 to 2006 [2]. Although the methods that govern
the application of economic evaluations can be equally applied to
pharmaceuticals and medical devices, there is currently asymme-
try in the way in which pharmaceuticals and devices are regulated
[3]. With a few exceptions, most of the literature on the use of
health economic evaluations was concerned with health eco-
nomic evaluations in general [1,4–8].
This means that there is a lack of reviews considering the
use of health economic evaluations in the pharmaceutical con-
text; that is, who are the decision makers at the macro, meso,
and micro levels and which factors or criteria do they use, in
which situations and contexts are these factors/criteria used,
and what are the barriers to their use. This leads to the objec-
tives that this literature review intended to investigate: 1) which
factors or criteria are used in priority setting of pharmaceuti-
cals, 2) in what contexts are health economic evaluations used
(or not used if specified), and 3) what are the barriers to use of
health economic evaluations at micro, meso, and macro health-
care levels?
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588 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 7 – 5 9 9Methods
The methods used were based on the methodology proposed by
the Centre for Reviews and Dissemination at the British National
Institute for Health Research, York University [9].
Review of previously published systematic literature reviews
This review began with a search for previously conducted system-
atic literature reviews on the subject of interest found in the
PubMed, Cochrane Database of Systematic Reviews, CINAHL, and
PsycINFO databases. The titles and abstracts of the results of these
searches were also browsed for potentially relevant articles. Hard
copies of potentially relevant reports were obtained. Articles were
to be included in this review if they satisfied the following criteria:
● Study design: Based on empirical data and using any of the
following qualitative and/or quantitative methods,
● Population in included studies in review: decision makers at
macro, meso, or micro health-care level,
● Study objectives: 1) assessments or description of pharmaceu-
tical-related priority-setting processes (i.e., how decisions are
made and based on what grounds; 2) assessments of barriers to
the use of economic evaluations; or 3) assessments of the con-
textual use of health economic evaluations in pharmaceutical
priority setting.
Although the author was responsible for all data extractions,
a senior researcher was consulted to audit the search and de-
cide on borderline studies. Disagreements were resolved by dis-
cussion, and, if needed, a third researcher was available for the
final decision making. All decisions were recorded, and all ex-
cluded reviews were assessed for relevance to other sections of
this review. The quality and findings of the included reviews
were reported textually. The author has not conducted a quan-
titative meta-analysis, but instead reported in text (qualita-
tively) the important results from various studies.
In total, four systematic reviews were identified [10 –13].
Three of these reviews failed to define what they meant by eco-
nomic information and/or cost-effectiveness [10 –12], and in one
[13], cost-effectiveness was not the main focus of the review,
resulting in continued uncertainty regarding the use of formal
health economic evaluations. No review covered all three
health-care levels, and none included the micro level. Three of
the four analyses investigated the use of factors and/or criteria
used in decision making and/or the barriers to use of economic
evaluations [10 –12]. The only review to consider the contextual
nature of the factors or criteria used did not have health eco-
nomic evaluations as a primary focus [13].
Review of empirical studies of pharmaceutical priority
setting
The search for empirical articles took its departure from the
MeSH index (Medical Substance Heading). The following search
terms were used: “economic evaluation,” “cost-effectiveness
analysis,” “cost-utility analysis,” “cost-benefit analysis,” “phar-
macoeconomic” in combination with either of the following
search terms “drug cost(s),” “eligibility determination,” “deci-
sion-making,” “rationing,” and “formulary.” Consequently, the
search terms were used in pairs following a predefined pattern.
The final electronic search strategy was developed through a
process of refining and revising search terms with the aim of
maximizing the number relevant articles retrieved. The follow-
ing databases were searched; PubMed, EconLit, Cochrane, Web
of Science, CINAHL, and PsycINFO. In addition, a number of
peer-reviewed journals such as Social Science of Medicine, Health
Policy, Applied Health Economics, European Journal of Health Econom-ics, Journal of Health Economics, Health Economics, Value in Health,
and Pharmacoeconomics were searched by hand.
Studies were included that satisfied the following criteria:
. Study design: Is the study based on empirical data and using
either or any of the following qualitative and/or quantitative
methods: observation of meetings, document analysis, inter-
views or surveys (telephone or postal)?
. Study subjects: Macro, meso, and micro health-care decision
makers;
. Study object: Pharmaceutical priority setting;
. Formal economic evaluations: Does the study indicate use or
lack of use of cost-effectiveness analysis or any formal health
economic evaluation?
. Publication date: Published between 1990 and May 2009;
. Language: English or Swedish.
Other materials such as editorials, letters, comments, and
ews were excluded from the review, as well as studies report-
ng on priority setting of non-pharmaceuticals. The search was
estricted to articles in the English or the Swedish language,
asically because of the language barrier and lack of financial
unding for translational services. In addition, studies pub-
ished before 1990 were excluded from the search because of the
ow frequency of economic evaluations published before 1990,
ndicating a low interest in such analyses among decision mak-
rs, as well as studies based on samples consisting entirely or
artly of researchers. The search identified more than 3100 ar-
icles, which were screened for relevance. Ninety-one poten-
ially relevant studies were selected for further investigation of
elevance but only 31 of these articles showed empirically the
nfluence of health economic evaluations in a pharmaceutical
riority-setting context. Reference lists in the articles identified
ere also searched for more studies to include in the review. A
anel of leading Swedish experts in health economics was con-
ulted to identify studies not recorded in the databases and
ournals already researched. This did, however, not result in
ny additional studies identified (Fig. 1).
Data extraction and reporting
The data extraction form was designed by the author and tested
on a sample of studies before data extraction began in collabora-
tion with a university librarian and a senior researcher. The char-
acteristics of the studies were described, and a synthesis of the
findings of the primary studies was provided. Data were recorded
about the author(s), year of the study, sample and sample size,
methods, study focus, and main findings. The latter implied fac-
tor/criteria reported in studies, the contexts in which formal eco-
Fig. 1 – Pharmaceutical priority setting.nomic evaluations were used/not used, and barriers to the use of
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sion criteria were included in the analysis.
Results
Articles that evaluated the use of health economic evaluations at
all three health-care levels were of specific interest in the review.
Unfortunately, no such study was identified. For this reason, the
findings from each level of decision makers (macro, meso, and
micro) are reported individually.
Description of study populations
Macro level
The majority of studies were conducted in the US, Canada, and
Australia (Table 1). The remaining articles were primarily based on
results or work performed in Sweden, the UK, and France. Reim-
bursement agencies or formulary committee members were the
most frequently sampled groups, and the most commonly used
methods were interviews (8 studies) and document analysis
(7 studies). Most studies, however, used both interviews and doc-
ument analysis, and a few studies also observed group delibera-
tions. Postal and telephone surveys were the least frequently used
method (4 studies), and these studies were mostly published in the
late 1990s or the early 2000s.
Meso level
The meso-level studies were mainly conducted in the UK and
the US. Other studies were conducted in Sweden, Canada,
France, Germany, The Netherlands, or France. A majority of the
decision makers investigated were members of a hospital for-
mulary committee, although the French study included phar-
macists in hospitals and clinics and the Swedish study included
regional county council formulary committee members (Table
). The most commonly used method to investigate meso-level
riority setting was postal and telephone surveys, followed by
bservation of group deliberations, interviews, and document
nalysis. Four of the studies used more than one research
ethod [14 –17].
Micro level
Five studies of the use of health economic evaluations at the micro
level were identified in the review (Table 3). Two of these were con-
ducted in the US, and one each in Greece, the UK, and Sweden. Al-
though two of the US-based studies sampled only specialists [18,19],
the Greek [20] and Swedish [21] studies sampled both general practi-
tioners (GPs) and specialists. In addition, one study sampled physi-
cians and pharmacists [22]. Postal survey was used as the method of
research without exception.
Factors and criteria used in priority setting
Macro level
Most of the macro level studies found a strong ordinal approach
to the way in which the criteria and analyses were considered:
first clinical efficacy (sometimes defined as clinical effective-
ness), safety, and then cost-effectiveness. There were, however,
some differences across settings in terms of the use of the cost-
effectiveness criterion. The cost-effectiveness criterion has
been reported to be used more frequently in centralized Euro-
pean health-care systems than in more decentralized systems
such as one in the US or Canada, Still, the review identifies
exceptions to this observation. In the US, managed care organi-
zations (MCOs), for instance, have also been reported to incor-
porate cost-effectiveness [23], whereas Grabowski and Mullins[24] report the availability of generic substitutes (substitutabil-
ity) as a prerequisite for costs to be considered at all by phar-
macy benefit management (PBM) companies. In addition, a
number of other less frequently used but still important criteria
have been reported in the MCO setting: standards of practice,
manufacturers’ rebate, impact on existing formulary products,
patient compliance, and available material from the US Food
and Drug Administration [25]. Cancer care in Canada has been
reported to also consider a number of criteria, in addition to
efficacy, including magnitude of benefit, quality of evidence,
alternative treatments available, cost per month, average dura-
tion of treatment, total populations affected, total yearly cost to
the system (budget impact), pressure from physicians and
patient groups, and historical precedent [26]. In Australia, cost
to the government has also been identified as an important
criterion [27]. In some countries, the criteria to be used have
been legislated. In Sweden, for instance, an application for re-
imbursement must, according to the Swedish Act on Pharma-
ceutical Benefits, be evaluated on the basis of four criteria: the
principles of human dignity, need and solidarity, cost-effective-
ness, and marginal benefit (in order of importance).
Meso level
Similar to macro-level decision makers, meso-level decision
makers favor drug efficacy and safety concerns above cost con-
siderations. An explicit use of the formal cost-effectiveness cri-
terion was, however, only indicated in a survey of attitudes
across Swedish regional formulary committees [28]. In an ob-
servational study, Erntoft [17] found that the use of the cost-
effectiveness criterion by a Swedish formulary committee var-
ied during four phases identified in the priority-setting process.
The criterion was more important in the first two phases, prep-
aration of decision making and expert comments, and less im-
portant during the final phases, decision making and launching
of the formulary and consequently not explicitly used. In hos-
pital formulary settings, the cost-effectiveness criterion was
usually defined as budget impact [29], acquisition cost or costs
weighted by benefits [30], cost of the drug compared to current
drug cost (alternative cost), informal cost-effectiveness [14],
cost per dose or unit time [31], or immediately covered costs
rather than long-term savings [32].
In addition to these frequently ranked criteria related to ef-
ficacy, safety, and cost-effectiveness, a number of more prag-
matic criteria were reported; easier dosing [33], timely deliver-
ies and length of time on the market [28], extent of drug
monitoring and avoidance of the use of home infusions [30],
ability of a nurse or medical attendant to administer the drug
and comparative drug use in other hospitals [14], relations be-
tween decision makers and the pharmaceutical industry [34],
the size of the clinical problem, the scale of the potential invest-
ment, acceptance from the budget holder [35], and pressure
from clinicians [16].
Micro level
Three of the five identified postal surveys of micro-level deci-
sion makers asked about the ranking of decision criteria [20 –22].
Based on these three reports, there seemed to be differences
among different types of prescribing physicians (GPs or special-
ists) and between physicians and pharmacists. All respective
groups agreed to the previously reported ordinal ranking of ef-
ficacy and other clinical issues (i.e., safety and side effects).
Although physicians tended to rank patient compliance higher
than cost-effectiveness [21], pharmacists were instead more in-
terested in acquisition cost and budgetary overspend than cost-
effectiveness [22].
590 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 7 – 5 9 9Table 1 – Summary of macro level studies included in the review (chronological order).
Author(s)
(year)
Settings Data sources Factors/criteria/
information
Use in context Barriers
Hailey (1997) PBAC (Australia),
reimbursement
decisions
Interviews,
participant
observation of
deliberations
Efficacy, safety,
cost-
effectiveness
Reject or limit listing; health
economic evaluations
were claimed when the
cost to the pharmaceutical
benefits program was a
major consideration, the
treatment was not cost-
effective, it was not
intended for a life-
threatening condition, and
there were other
treatments available, cost-
effectiveness depended
critically on subgroup
analysis or the validity of
assumptions made about
long-term effectiveness
Efficacy superior to cost-
effectiveness, limited
evidence of effectiveness,
pressure from the public,
political judgment
Lyles et al.
(1997)
51 managed care
organizations
in the US,
formulary
decisions
Telephone survey Clinical
effectiveness,
safety, cost of
treatment, cost-
effectiveness,
quality of life
N/A N/A
Grabowski and
Mullins
(1997)
PBM companies
in the US,
formulary
decisions
Interviews,
documentary
analysis
Efficacy, safety,
substitutability
(if substitutable,
also cost)
N/A Lack of studies comparing
substitutable
pharmaceuticals,
methodological issues
(e.g., transferability,
discount rates,
measurement of cost and
benefits, industry bias)
Evans et al.
(2000)
MCOs in the US,
formulary
decisions
Telephone survey
(21 medical and
20 pharmacy
directors)
Medical directors:
efficacy, safety,
and cost-
effectiveness.
Pharmacy
directors: safety,
efficacy, cost-
effectiveness
66% of medical directors, but
none of the pharmacy
directors reported it as
somewhat or very
important in influencing
the speed of approval
Reliance on assumptions;
methodological issues
(transferability), lack of
health economic
competence
Cox et al. (2000) Managed care
and PBM
decision
makers in the
US, general
concepts
Telephone
interviews
(n  16)
N/A N/A Copay precludes the
relevance of willingness
to pay, limited scope with
regard to local budgets,
difficult to understand
Grizzle et al.
(2000)
Managed care
decision
makers in the
US
Telephone
interviews
Add a drug to the formulary Difficult to understand,
irrelevant to the
organization, lack of
studies of relevant data
Martin et al.
(2001)
Cancer Care
Ontario Policy
Advisory
Committee
(Canada),
formulary
decisions
Document
analysis,
interviews,
observation of
deliberations
Efficacy
(magnitude of
clinical benefit),
quality of
evidence,
alternatives,
cost per month,
average
duration of
treatment, total
population of
patients
affected, total
cost to the
system (yearly),
pressure from
physician and
patient groups,
historical
precedent cases
Formal cost-effectiveness
analysis was rarely
available and not used;
however, the concept was
used informally
Institutions (actors) and
process(continued on next page)
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Author(s)
(year)
Settings Data sources Factors/criteria/information Use in context Barriers
West et al.
(2002)
Key provincial
informants in
five Canadian
provinces,
formulary
decisions
Postal survey Efficacy, cost per effect, cost per
dose, availability of alternative
therapy, cost compared to
available alternatives, impact
on total costs of drug benefit
programs, comparative safety
against alternative, cost per
treatment course, effect on
overall health-care costs in the
province, contribution to
current therapeutic
armamentarium, drug
compliance, patient
satisfaction with drug, efficacy
compared to that of placebo,
pharmacology, drug
interactions, chemistry
N/A Methodological issues
(transferability,
missing data),
industry bias
Anell (2004) PBAC (Australia),
DQTC
(Canada), PI
(Canada),
Pharmaceutical
Price Board
(Finland),
NICE (England
and Wales),
CdT (France)
Document
analysis,
interviews
Efficacy, clinical effectiveness Increase in importance when a
high potential budget
impact; decrease in
importance when the
clinical need increases
Lack of health economic
competence
Anell and
Persson
(2005)
TLV (Sweden),
reimbursement
decisions
Document
analysis
Human dignity, need and
solidarity, cost-effectiveness,
marginal benefit
Increases in importance when
high potential budget impact
and when cost-effectiveness
varies by indication and/or
subgroups of patients,
decrease in importance when
a lack of alternative
treatment therapies and
severe diseases
N/A
Jansson (2007) TLV (Sweden),
reimbursement
decisions
Document
analysis
(2002–2005),
interviews
Human dignity, need and
solidarity, cost-effectiveness,
marginal benefit
Major rationale for rejecting or
limit reimbursement,
increases in importance
when the demand for
openness and transparency
increased, decreases in
importance when a lack of
alternative treatment
therapies and severe
diseases
N/A
Bryan et al.
(2007)
NICE (England
and Wales),
formulary
decisions
Interviews,
observation
of
deliberations,
document
analysis
N/A Health economic evaluations
were used as a basis for
formulary decisions regarding
cancer drugs. Health
economic evaluations were
not suitable for bipolar I
disease.
Difficult to understand,
methodological issues
(uncertainty,
consistency,
assessment of
benefits in very
severe conditions,
irreversibility), ethical
considerations,
presentation (graphs,
disaggregation,
consequences), rule of
rescue, difficulties in
implementing
threshold values,
voluntary
implementation of
NICE guidelines
Williams et al.
(2007)
NICE (England
and Wales),
formulary
decisions
Semistructured
interviews,
observation
of
deliberations
Clinical effectiveness, cost-
effectiveness
Analytical framework,
informal use of health
economic evaluations
N/A(continued on next page)
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Macro level
There were large variations in the reported use of health economic
evaluations among the macro-level decision makers. Systematic
use of cost-effectiveness analysis was reported from the Pharma-
ceutical Benefits Advisory Committee (PBAC) in Australia [27,28],
the National Institute for Clinical Excellence (NICE) in England and
Wales [15,36], and the Swedish Dental and Pharmaceutical Bene-
fits Agency (TLV) [37,38]. In these reimbursement and clinical
guidelines agencies, increased use of health economic evaluations
was identified in situations with drugs with a large potential bud-
get impact and when cost-effectiveness varied by indication
and/or subgroups of patients. Based on observations of NICE’s
group deliberations, Williams et al. [36] reported that cost-effec-
iveness analysis in addition increased in importance when there
ere major disagreements among committee members regarding
he value of the clinical evidence and when cost-effectiveness
nalysis helped decision makers to structure committee discus-
ions and deliberations. Jansson [38] reported that the cost-effec-
iveness criterion was the major rationale for limiting or rejecting
overage by the TLV, which was suggested to be a result of a legis-
ative demand for a transparent priority-setting process. Harris et al.
27] analyzed all submissions containing estimated cost per quality-
djusted life-year (QALY) or cost per life-year gained (LYG) and sub-
itted to PBAC between 1994 and 2004. They found that those sub-
issions that contained a cost per QALY were more likely to be used
s last-line therapy than other submissions that were not QALY
ased. The use of economic modeling appeared to have only a small
Table 1 (continued)
Author(s)
(year)
Settings Data sources Factors/c
Harris et al.
(2008)
PBAC (Australia),
reimbursement
decisions
Document
analysis
(1994–2004)
Efficacy, c
to gove
resubm
CdT, Commission de Transparence; DQTC, Drug Quality and Therape
N/A, not available; NICE, National Institute for Clinical Excellence; PB
management; PI, Pharmacoeconomics Initiative (in British Columb
Pharmaceutical Benefits Agency; US, United States.ffect on the decisions to recommend coverage. In those cases inhich there was a strong political and/or public interest in the out-
ome of the process, the use of health economic evaluations seemed
o decrease [35]. In addition, in cases of orphan drugs and in situa-
ions in which there was a lack of alternative therapies (particularly
hen the illness to be treated was severe), the use of a cost-effective-
ess analysis was less commonly used [37].
In other settings, primarily the US and Canada but also some in
uropean countries, health economic evaluations seem to be used
ore informally [23,26] or in a very limited scope [24]. Anell [39]
otes, for example, that there was no evidence that the Pharma-
eutical Price Board in Finland used health economic evaluations
xplicitly in the beginning of the 2000s, despite the Finnish re-
uests for such data from manufacturers’ submission since the
arly 2000s. This observation was explained by the lack of health
conomic competence in the Finnish committee, which has also
een cited as an explanation of the lack of use of health economic
valuations in the French reimbursement system.
Meso level
There were few indications of meso-level decision makers using formal
health economic evaluations as a basis for pharmaceutical priority
setting. Rather researchers, for example, Späth et al. [34], highlight
the relevance of price and budget impact in the meso health-care
setting. According to Odedina et al. [30], the typical source of cost data
is in-house hospital data (75%), published literature (57%), pharma-
ceutical industry studies (9%), and other (2%). A qualitative observa-
tional study of Swedish regional county council formulary commit-
tees pointed to the use of formal cost-effectiveness analyses in the
ia/information Use in context Barriers
ffectiveness, cost
nt,
s
The rate of rejection was
higher for those with a
cost per QALY (47%)
than all submissions
(37%), similar to all
cost-effectiveness
analyses (50%) and
similar to those with a
cost per LYG (40%).
Those with a cost per
QALY were more likely
to be used as last-line
therapy than other
cost-effectiveness
submissions and
slightly more likely to
have been seen before.
The use of economic
modeling appeared to
have only a small
effect on the decision
to recommend
coverage, with the
translation from the
clinical evidence to
the final outcome of
QALYs in the model
having a small and
imprecisely estimated
impact.
Rule of rescue,
political pressures
Committee (in Ontario, Canada); MCOs, managed care organizations;
harmaceutical Benefits Advisory Committee; PBM, pharmacy benefit
nada); QALY, quality-adjusted life-year; TLV, Swedish Dental andriter
ost-e
rnme
ission
utics
AC, P
ia, Cainitial two phases of the priority-setting process [17]. Most other
593V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 7 – 5 9 9Table 2 – Summary of meso-level studies included in the review (chronological order).
Author(s)
(year)
Settings Methods Factors/criteria/information Use in context Barriers
Sloan et al.
(1997)
Managed care hospital
pharmacy formulary
in the US, hospital
formulary decisions
Telephone survey
(103 hospitals)
Reasons to add: high efficacy,
low cost, doctor’s request,
easier dosing, better than
existing drugs; reasons not to
add: drug not reviewed,
duplicate therapy or me-too
drug, clinically inferior, high
cost
Drug categories for which
pharmacists had seen
CEAs: gastrointestinal
drugs, antibiotics,
antithrombolytic
drugs, cardiovascular
drugs, adjunct of
coronary angioplasty,
antiasthmatic drugs,
nonsteroidal anti-
inflammatory drugs
Too few studies,
methodological
issues
(transferability),
lack of health
economic skills,
studies published
too late, industry
bias, accessibility
Anell and
Svarvar
(2000)
Swedish county council
formulary committee
members, formulary
decisions: regional
treatment guidelines
Postal survey (216
respondents)
Therapeutic effects, cost-
effectiveness, timely
deliveries, number of years
the drug has been on the
market, and perceived
reputation/credibility of the
company
N/A Lack of health
economic skills,
too few studies,
methodological
issues
(transferability)
Kulsomboon
et al. (2001)
Teaching hospitals in
the US
Postal survey (166
respondents)
N/A Developing treatment
guidelines, requesting
additional drug
budgets or placing
drugs on prior
authorization;
categories requiring
CEAs: antiplatelet
agents, systematic
anti-infective drugs,
and antineoplastic
agents, glycoprotein
IIb/IIIa inhibitors,
cyclooxygenase II
inhibitor, low-
molecular weight
heparin
Methodological
issues (modeling),
might expand if
the US FDA review
process
incorporated
approval of such
data
Odedina
et al. (2002)
Hospital formulary
committee members
(pharmacists) in the
US (Florida)
Telephone survey
(212
respondents)
Drug efficacy, drug toxicity,
side effects, acquisition cost,
costs weighted by benefits,
extent of drug monitoring,
availability of oral therapy,
average hospital length of
stay, in-house data, avoiding
the use of home infusions
N/A N/A
Martin et al.
(2003)
Committees involved in
hospital formularies
in teaching hospitals
in Canada (Toronto)
Document analysis
(20 documents),
interviews with
key informants
(18), and
observation of
group
deliberations (3
P&T meetings)
Complex cluster of factors:
efficacy, quality of evidence,
safety (adverse effects and
toxicity), number of patients,
administration of the drug,
hospital budget impact,
prescribing restrictions, and
informal cost-effectiveness
Highly contextual nature
of the decision-making
process; formal CEAs
were seldom used, but
cost data and informal
cost comparisons were
considered
Lack of studies,
institutions
(actors), process
Späth et al.
(2003)
Pharmacists in
hospitals (public-
global budgets) and
clinical departments
(private, fee for
service) in France
(Rhône-Alpes region)
Qualitative
interviews in 19
hospitals and
clinical
departments
Efficacy, safety, relations
between decision makers
and pharmaceutical
industry, patient quality of
life, economic criteria
Price and budget impact
were more important
in hospitals than in
clinical departments;
health economic
evaluations were very
rarely used
Lack of time and
resources to
collect and
analyze data, lack
of health
economics
competence,
institutions
(actors) and
process (budgets,
freedom of
prescription),
industry bias,
methodological
issues
(transferability)(continued on next page)
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Author(s)
(year)
Settings Methods Factors/criteria/information Use in context Barriers
Jenkings and
Barber
(2004)
Drug and therapeutics
committees in two
general hospitals
Observation of
group
deliberations
Efficacy, cost (per dose, per
unit of time, or total
annual expenditure),
pharmaceutical company
activities, doctor’s request,
patient demand, pre-
existing prescribing of a
new drug, decisions of
other DTCs, personality of
the applicant
Increases in importance
when relevant clinical
trial data were
equivocal or absent
and low costs
N/A
Haslé-Pham
et al. (2005)
Public hospital drug
formulary committee
members in France,
Germany, The
Netherlands, United
Kingdom
Postal survey (143
doctors and 169
pharmacists)
Efficacy (88%), health
economic analyses (78%),
patient-reported outcomes
(70%); most useful to have
an expert in
medicoeconomics (78%) at
the hospital
French and German
respondents used the
results from health
economic analyses less
frequently than the
English and Dutch
respondents.
Pharmacists and
specialists were more
frequently interested
in CEAs than GPs.
Lack of health
economic
competence,
methodological
issues
(transferability)
Williams and
Bryan et al.
(2007)
Trusts, county-wide
priorities network,
hospital medicine
management
committee, primary
care area medicines
management,
interface medicines
management
committee
Postal survey (101
trusts),
observation of
committee
meetings,
documentary
analysis,
interviews
Efficacy, short-term cost, size
of the clinical problem,
scale of the potential
investment, expected
number of potential
patients, implementation
considerations, signature
of budget holder
Health economic
analyses were only
requested in a small
number of cases in
primary and secondary
care. Priorities
networks made more
use of health
technology assessment
and other research
evidence. Other
committees focused
more on practical
implementation issues
of whether and how to
restrict use and control
prescribing.
Lack of health
economic
competence,
accessibility
of timely
analyses,
industry bias,
inability to
realize
savings in
practice,
ethical
considerations,
methodological
issues
(variation in
methodologies,
robustness)
Chen et al.
(2007)
Hospital medicine
management
committees
(pharmacists), new
drug applications (6)
Observation of
committee
meetings,
interviews (10
interviewees)
Published reviews, efficacy,
safety, acquisition cost,
decisions made in other
hospitals, doctor’s request
Increased in importance
when backing up the
decisions that had
already been made
Accessibility of
timely
analyses, lack
of health
economic
competence,
preference for
cost-
effectiveness
data collected
in clinical
trials,
methodological
issues
(transferability),
lack of
experience in
searching for
evidence in
economic
databases,
industry bias,
limited scope
with regard to
local budgets,
presentation
(aggregated)(continued on next page)
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595V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 7 – 5 9 9studies investigating meso-level priority settings found less than
stringent definitions of pharmacoeconomic data.
Similar to macro-level priority setting, the use of cost-effective-
ness analyses increased if the potential budget impact was large, but
also when there were new drugs that had recently been approved by
reimbursement agencies. Examples of groups of drugs that fell into
this category were antithrombolytic drugs, cardiovascular drugs, an-
tiasthmatic drugs [33], glycoprotein IIb/IIIa, cyclooxygenase II inhib-
itors, and low-molecular weight heparin [29]. Cost-effectiveness
analysis has also been reported as a vehicle for motivating supple-
mentary drug budgets or for placing drugs on prior authorization [29].
Based on observations of British Drug and Therapeutics Committees
in two general hospitals, Jenkings and Barber [31] noted that the im-
portance of costs increased when clinical trial data were ambiguous
or absent. Another situation that spurred the use of cost-effective-
ness analysis was the occurrence of a health economics–oriented
national reimbursement agency. A survey among public hospital
drug formulary committee members in France, Germany, The Neth-
erlands, and the UK indicated that French and German respondents
used the results of health economic evaluations less frequently than
the English and Dutch respondents [40]. Cost-effectiveness has also
proven to be useful to meso-level decision makers to support previ-
ous decisions [15].
Micro level
No identified article investigated the contextual use of health eco-
nomic evaluations in local-level decision making. Jansson and
Anell [21], however, were close by investigating the importance of
costs in different settings. They found that there were three situ-
ations in which costs were relatively important: 1) when the phy-
sician had to choose between two or more generic drugs; 2) when
the patient=s illness or discomfort was of low priority (to the phy-
sician); and 3) when the patient did not request a specific drug.
Barriers to the use of health economic evaluations
Macro level
According to Hailey [35], a key to the successful use of economic
analysis at PBAC has been the availability of a well-developed
framework for evaluations linked to legislative provisions and
clearly defined responsibilities within a government program.
Harris et al. [27] note that political pressures, especially in cases of
life-threatening conditions, have been the greatest threat to the
Australian system. Based on the study of six macro-level decision-
making bodies in Australia, Canada, Finland, the UK, and France,
Anell [39] suggests that one major barrier to the explicit use of
Table 2 (continued)
Author(s)
(year)
Settings Methods Facto
Erntoft (2010) County council
formulary committee
members in Sweden
Observation of
committee
meetings (n  7),
interviews
Medica
trad
(cos
cons
new
adm
envi
CEAs, cost-effectiveness analyses; FDA, Food and Drug Administra
therapeutics; US, United States.ealth economic evaluations was the lack of health economics gompetence across committees. Both Cox et al. [41] and Grizzle et
l. [42] note that decision makers find economic evaluations diffi-
ult to understand. Bryan et al. [36] argue that despite the exten-
ive use of health economic evaluations by NICE, there was vari-
bility among committee members regarding the understanding
f cost-effectiveness analysis. A number of additional issues re-
ated to the use of QALYs have also been identified in the NICE
etting. Such examples are the lack of equity concerns in cost-
ffectiveness analyses, the preferences for disaggregated mea-
ures, and failure of QALYs as an outcome when it comes to incor-
orating issues of disease irreversibility or assessing benefits in
ituations of very severe conditions. In addition, problems such as
ifficulties in implementing threshold values and the lack of
raphic presentations of models (presentational improvements
eeded) have been identified in the NICE setting. In managed care
rganizations (the US setting), a number of barriers have been
eported including methodological issues (reliance on assump-
ions, lack of generalizability, discount rates, and concerns about
he objectivity of firm-sponsored cost-effectiveness analyses)
23,24]. Key provincial respondents in a survey of five Canadian
rovinces stated concerns about missing data on a variety of is-
ues such as effects of real-life costs and data associated with
ositive effects (e.g., fewer hospitalizations) [43]. Decision makers
ave also reported manufacturer provided models as unconvinc-
ng when it comes to estimating effectiveness in the Canadian
etting.
Meso level
At the meso level, the most frequently mentioned barrier was the
lack of applicability of cost-effectiveness analyses to hospital set-
tings [14,16,33,34,40]. The lack of timely evaluations and the lack of
time, resources, and competence to collect and analyze cost-effec-
tiveness data were also perceived as considerable barriers in many
studies. Other barriers reported in the meso-level health-care set-
ting were skepticism toward modeling [29], closed budgets [34], a
erceived bias in studies to the favor of the manufacturer, inability
o realize savings in clinical practice, ethical objections and pref-
rences for disaggregated measures instead of indices like QALYs
15], and switches between scientific and practical rationality
practical issues) [17].
Micro level
Only one of the five micro-level studies included in this review re-
ported some form of evidence of barriers to the use of cost-effective-
ness analyses. The study by Walley et al. [22] investigated British
harmaceutical advisors, indicating that there were differences re-
iteria/information Use in context Barriers
ropriateness, medical
health economics
ctiveness), monetary
nces, elderly patients,
maceuticals,
ative improvements,
ental concerns
Health economic
evaluations were used
in the two phases of
the process; when
preparing and during
expert comments.
When making
decisions and
launching the
formulary, the health
economics factor was
defined as price.
Switches
between
scientific
rationale and
local
rationale
(practical
issues),
industry bias,
lack of health
economics
competence
GPs, general practitioners; N/A, not available; P&T, pharmacy andrs/cr
l app
ition,
t-effe
eque
phar
inistr
ronm
tion;arding the perceived barriers to the use of health economic evalua-
i
a
is; US
596 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 7 – 5 9 9tions between prescribing physicians and pharmaceutical advisors.
The major barriers, as perceived by the advisors, were the inflexibil-
ity of the existing National Healthcare System structures and a lack
of credibility of the evaluations. In addition, a Swedish study [21] also
nvestigated barriers, but the objective was rather cost consider-
Table 3 – Summary of micro level studies included in the r
Author(s) (year) Settings Methods
Brody et al. (1991) Hospital physicians
in the US: choice
between two
similar drugs
(myocardial
infarction)
Postal
survey
(2200
respondents)
Kangis and van
der Geer (1996)
GPs and specialists
in Greece:
intention to
prescribe
Survey (60
respondents)
Walley et al.
(1997)
Pharmaceutical
advisors in
England, Wales,
and Scotland:
prescribing
advice
Postal
survey
(178
respondents)
Erkan et al. (2002) Specialists
(rheumatologists)
in the US:
intention to
prescribe
Postal
survey
(375
respondents)
Jansson and Anell
(2006)
GPs and specialists
in Sweden:
intention to
prescribe
Postal
survey
(738
respondents)
GPs, general practitioners; N/A, not available; RA, rheumatoid arthrittions in general.Discussion
Despite the fact that this review was not limited to location of liter-
ature, it is likely that the searches for literature have been inherently
(chronological order).
ctors/criteria Use in context Barriers
nomic
onsiderations
ERE the
ain reason
or their choice
Two different groups
of physicians:
cost-conscious
group (less
expensive and
insufficient
evidence to
determine which
drug is better) and
the rationing
group (there may
be additional
benefit, but
insufficient to
justify its extra
cost)
N/A
cacy, safety,
onvenience,
cientific
vidence,
rademark,
oodwill, price
per pack,
reatment vs.
ompetition),
eimbursement
tatus
The intention of
prescribing a
pharmaceutical
was significantly
changed after
viewing health
economic
evaluation
N/A
nical issues,
conomic
onsiderations
Actually discussed:
drug acquisition
cost and
budgetary
overspending.
Would ideally like
to discuss: cost-
effectiveness from
a societal
perspective
Budget structures,
industry bias
cacy, cost-
ffectiveness
When cost is
considered,
physicians may
limit their options
for first-line
treatment of RA;
health economic
analyses appear to
play a dominant
role in
rheumatologists’
choice of treatment
regimens, at times
contrary to the
physician’s
perception of the
effectiveness of a
drug
N/A
cacy, side
ffects,
ompliance,
ost-
ffectiveness
N/A N/A
, United States.eview
Fa
Eco
c
W
m
f
Effi
c
s
e
t
g
(
t
c
r
s
Cli
e
c
Effi
e
Effi
e
c
c
ebiased toward more recent publications and studies written in the
l
(
u
m
t
o
m
b
m
i
s
597V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 7 – 5 9 9English language. Another limitation of the methodology is the lack
of quantification of the results into a meta-analysis because of the
problems of separating the local context from the use and hence the
outcome. Instead, richer descriptions of studies are provided in place
of quantifications of results. Yet another limitation is the single au-
thorship of the review, which may have resulted in reviewer selec-
tion bias. To reduce this potential bias, the selection of articles to
include in this review was supported by a senior researcher. Fortu-
nately, there were no differences regarding the inclusion of studies,
but in case of this situation, the author had access to a third senior
researcher with decision power.
Study populations
With these limitations in mind, it is suggested that the study popu-
lations were clearly dominated by English-speaking countries such
as the US, the UK, Canada, and Australia. Only a few more countries
have been investigated regarding this subject, and all of these were
European (Sweden, Finland, France, Germany, The Netherlands, and
Greece). This review suggests that, to date, only three countries had
investigated the use of health economic evaluations at all three
health-care levels: the US, the UK, and Sweden.
Postal and telephone survey methods dominated (n  17), fol-
owed by studies based on interviews (n  13), document analysis
n 10), and observation of group deliberations (n 9). The methods
sed, however, were different at the three health-care levels. At the
acro and meso levels, multiple methods were commonly used. At
he micro level, postal survey was the only method used. Altogether,
bservation of group deliberations was the least used method. This
ay at least in part be explained as an access problem.
A majority (79%) of studies at the macro level were published
etween 2000 and 2008. The corresponding figures for meso- and
icro-level decision makers were 92% and 40%, respectively. This
ndicates an increased (reported) use of economic evaluations in this
Table 4 – Overview of factors/criteria used in priority settin
evaluations (macro, meso, and micro health-care levels).
Setting Macro health-care level
Factors/criteria used
in priority setting
Efficacy (clinical
effectiveness), safety,
cost-effectiveness
Contextual use of
economic
evaluations
Large budget impact,
subgroups of patients,
differences in
interpreting clinical
evidence, structuring
process
Barriers to use of
economic
evaluations
Unconvincing modeling,
lack of health economic
skills, equity concerns,
preference for
disaggregated measures,
unfavorable
presentation, difficult to
implement threshold
values, implicit priority
setting processetting during the past decade, at least at macro and meso levels.Factors and criteria used in priority setting
This review suggests that efficacy and safety were the most impor-
tant decision criteria used at all three health-care levels investigated
(Table 4). The cost-effectiveness criterion was more important at a
macro health-care level, whereas the reported use of the cost-effec-
tiveness criterion was rather vague at meso and micro health-care
levels. At these latter health-care levels, cost-effectiveness was de-
fined in multiple ways (e.g., budget impact, informal cost-effective-
ness, and cost per dose). These varied elements of costs considered in
hospital and DTC priority setting have been confirmed by Walkom et
al. [12]. One possible explanation may be the fact that there are few
health economists practicing at those levels, and the knowledge of
cost-effectiveness techniques consequently is scarce. These defini-
tions may be seen as a second best alternative to cost-effectiveness
or translations of the definition of cost-effectiveness, which are bet-
ter suited to the institutional context. One example of this is the
differences between physicians and pharmacists at the micro level in
terms of the ranking of costs. Physicians ranked cost-effectiveness
and price per pack next after patient compliance, whereas pharma-
ceutical advisors ranked acquisition costs and budget impact. In this
case, both groups were reported to understand the concept of cost-
effectiveness, but the incentive structure seemed to be different be-
tween physicians and pharmaceutical advisors. As noted by Vouren-
koski et al. [13], use of subjective and value-based criteria has proved
rational and legitimate in real-life priority setting.
Contextual use of health economic evaluations
Although most articles at the macro level contained some in-
formation regarding contextual use in terms of cases of deci-
sions, this information was not available in any study at the
micro level. Although decision makers at the macro level
seemed to be rather orthodox in their use of health economic
ntextual use of, and barriers to use of economic
Meso health-care level Micro health-care level
Efficacy (clinical
effectiveness), safety,
cost (cost-
effectiveness,
acquisition price, per
treatment)
Efficacy (clinical
effectiveness), safety,
side effects,
compliance, cost (cost-
effectiveness,
acquisition price, per
treatment)
Large budget impact,
reimbursement
agencies’ interest in
cost-effectiveness,
request budgets, lack of
clinical trial data,
motivating decisions
already made,
preparation and expert
comments
No relevant studies
Mistrust of modeling, lack
of HE skills, equity
concerns, preference
for disaggregated
measures,
manufacturer bias,
lack of applicability to
settings, lack of timely
studies, rigid budget
structures, unrealizable
savings, scientific and
local rationalities
Manufacturer bias, rigid
budget structuresg, coevaluations, meso-level decision makers seemed to be more
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598 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 7 – 5 9 9creative. For instance, Williams and Bryan [15] reported cost-
effectiveness being used to legitimize decisions, which, in fact,
had never been backed up by this kind of information. This may
be connected with the reported increased use of cost-effective-
ness analysis among public drug formulary members in coun-
tries with a health economics– oriented national reimburse-
ment agency [40].
This review suggests further that the existence of explicit priority-
setting processes increased the use of cost-effectiveness as both crite-
rionandrationale,butalso improvedthestructureof thedecision-mak-
ing process. The more informal use of health economic evaluations in
North America (US and Canada) may be a consequence of a tradition of
implicit priority-setting processes. A similar conclusion was made by
Neumann [44] when exploring the use of cost-effectiveness analysis in
the US. Other situations that increased the use of health economic eval-
uations were reimbursement and formulary decisions regarding phar-
maceuticals with a large potential budget impact and subgroups of pa-
tients, when patient groups were lacking power or legitimacy to protest
against priority-setting decisions, when high qualitative clinical trial
data were missing, or when requesting additional budgets to finance
the use of expensive pharmaceuticals.
Barriers to use of health economic evaluations
In a review of the general use of health economic evaluations, Ed-
dama and Coast [8] suggested that the barriers to use at the meso and
icro levels can be divided into three categories: institutional and
olitical factors (i.e., inflexibility of budgets and political objectives),
ultural reasons (i.e., evidence of effectiveness more important than
osts, individual patient vs. population perspective, lack of time and
imeliness of economic evaluation), and methodological factors (i.e.,
ssumptions in economic evaluations, lack of relevance). Most of
hese categories of barriers were also visible in pharmaceutical pri-
rity setting; however, there were differences between the health-
are levels. Although meso- and mirco-level decision makers re-
orted shared barriers such as rigid budget structures, this did not
eem to be a major problem at the macro level. This may be ex-
lained by the fact that some macro-level decision makers did not
ave responsibility for drug expenditures. This was a common fea-
ure among the macro-level decision makers that have reported use
f health economic evaluations in this review: NICE, PBAC, and TLV.
n addition, a study included in this review [40] found that the occur-
rence of health economic–oriented macro-level decision makers ac-
tually seemed to spur the interest in using health economic evalua-
tions at the meso level. This suggests that there is a mimicking factor
to consider in the use of health economic evaluations, i.e., decision
makers adapt their decision making to other related institutions that
are respected, thus legitimizing their own activities.
Political objectives have been suggested to decrease the use of
health economic evaluations at the meso level [8]. The equity con-
cern expressed by health-care decision makers at the macro and
meso levels may be seen as a political barrier to the use of health
economic evaluations. In addition, other cultural barriers such as the
lack of (or the uneven distribution of) health economics skills to eval-
uate the models, discontentment with being provided aggregated
measures, and a strong preference for disaggregated ones have been
reported in this review. The preference for disaggregated measures
may be explained by the incompatibility between the strategies nor-
mally used to reduce uncertainty in medical decision making and a
calibrated measure such as QALYs [17]. Other cultural barriers at the
meso level included issues such as unrealizable savings and lack of
timely studies.
The remaining barriers identified in this review would probably cor-
respondtomethodologicalbarriers. Interestingly, thesebarriersseemto
be minor (in terms of number of mentioning; the conclusion drawn
regarding the pattern identified was based on frequency of mentioning
it as a barrier in the articles reviewed) compared with political and cul-tural ones. Macro and meso health-care level decision makers, how-
ever, shared some similarities such as the mistrust of manufacturer-
provided models, preference for health-care perspectives rather than
societal perspectives, and lack of transferability of results to other set-
tings.
Conclusion
This review investigates the factors and criteria used in pharmaceutical
priority setting, the context-dependent use of health economic evalua-
tions, and barriers to use at the macro, meso, and micro health-care
levels. The cost-effectiveness criterion was MOST important TO macro-
level decision makers, whereas the reported use of the cost-effective-
ness criterion among meso- and micro-level health-care decision mak-
ers was rather vague. The barriers to the use of health economic
evaluations had elements of institutional-political, cultural, and meth-
odological issues. Factors that seem to support an increased use of
health economics evaluations in pharmaceutical priority setting are
well-developedframeworks forevaluations, thepresenceofhealtheco-
nomics competence among decision makers, and explicit priority-set-
ting processes. This review suggests that there are differences in how
economic evaluations are used at the macro, meso, and micro levels,
mainlybecauseofdifferencesintherationaleateachlevel.Asuggestion
forfutureresearchistoanalyzetwoorall threehealth-carelevelssimul-
taneously to compare the uses. This is expected to increase the compa-
rability of the use in different settings.
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